Childhood Epilepsy Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. Seizures result from abnormal electrical discharges in the brain and vary in their manifestations, from the brief staring spells that are characteristic of absence seizures, to full-body convulsions known as tonic-clonic seizures. Seizures in children are among the most common neurological disorders.

The childhood epilepsy market report includes an assessment of the pipeline and the clinical and commercial landscapes of childhood epilepsy, along with an analysis of key market events and the future competitive environment.

What are the market dynamics in the childhood epilepsy therapeutics industry?

Focal (partial) seizures are the most frequent seizure type at all ages, but early-onset epilepsies, particularly those with infancy onset, are characterized by higher proportions of generalized seizures and epileptic spasms. Early-onset epilepsies are more likely to have a demonstrable cause, with structural and genetic causes being the most common. This shows the importance of including neuroimaging and genetic investigations in clinical care, especially for early-onset epilepsies. Childhood epilepsy has a large spectrum of clinical manifestations, and many other conditions may resemble epilepsy. This often makes the diagnostic process challenging, with a considerable risk of misdiagnosis.

The incidence of childhood epilepsy varies between industrialized countries and developing ones. Higher incidence is reported from underdeveloped countries, particularly from rural areas. Incidence of childhood epilepsy is higher in males than in females. The incidence is consistently reported to be highest in the first year of life and declines to adult levels by the end of the first decade. The mortality rate in people affected by epilepsy is 2–4 times higher than the rest of the population, and 5–10 times higher in children.

The mainstay of epilepsy treatment revolves around the use of anti-epileptic drugs (AEDs) to treat and prevent the occurrence of seizures. A multitude of AED products are currently available, many of which are now available as inexpensive generics, making the childhood epilepsy market competitive and crowded. The choice of AED to prescribe can be difficult and depends on several factors such as type of seizures or epilepsy syndrome, age, comorbidities, drug interactions, efficacy, side-effect profile, and cost.  For focal seizures, carbamazepine is traditionally prescribed as the first-line treatment. However, most patients soon switch to similarly efficacious therapies with better tolerability. These include levetiracetam, lamotrigine, as well as later-generation versions of carbamazepine such as oxcarbazepine. Sodium valproate and topiramate are also commonly used for focal seizures.

Which are the key regions in the childhood epilepsy market?

The US, Europe, and Asia-Pacific are the key regions in the childhood epilepsy market. The US has the highest number of clinical trials for childhood epilepsy, followed by Europe and Asia-Pacific.

Which are the key phases in the childhood epilepsy market?

The key phases in the childhood epilepsy market include phase I, phase II, phase III, phase IV, phase I/II, and phase II/III.

There are 68 ongoing/planned Phase 0-Phase IV interventional studies being conducted for childhood epilepsy, with the majority in Phase II. The high number of completed Phase III trials highlights the mature nature of the childhood epilepsy market.

Childhood epilepsy market, by phase

Childhood epilepsy market, by phase

For more phase insights, download a free sample

What are the top targets for drug development in the childhood epilepsy market?

The gamma-aminobutyric acid type A receptor subunit, G protein coupled receptor 55 (GPR55), voltage gated sodium channel (SCN, and 5-hydroxytryptamine receptor 2C (5 HT2C) are the top targets for drug development in the childhood epilepsy market.

The gamma-aminobutyric acid type A receptor subunit (GABA(A) receptor) has emerged as a key target for most of the pipeline candidates within the childhood epilepsy space.

What are top drugs in the childhood epilepsy market?

Rufinamide, Clobazam, Cannabidiol, Sulthiame, Corticotropin, Cosyntropin are the top drugs in the childhood epilepsy market.

Childhood epilepsy market, by drugs

Childhood epilepsy market, by drugs

For more drug insights, download a free sample

Who are the major sponsors in the childhood epilepsy market?

Abbott Laboratories, GW Pharmaceuticals, Takeda Pharmaceutical, Eisai, UCB, Zogenix, Rinpharm are few of the top sponsors in the childhood epilepsy market.

Abbott Laboratories ranks as the top sponsor in childhood epilepsy clinical research with 18 clinical trials. After Abbott, the most active sponsors of childhood epilepsy clinical trials are SK Biopharm and Rinpharm.

Childhood epilepsy market, by sponsor

Childhood epilepsy market, by sponsor

To know more about key sponsors, download a free sample

Market report scope

Top drugs Rufinamide, Clobazam, Cannabidiol, Sulthiame, Corticotropin, Cosyntropin
Key Phases Phase I, phase II, phase III, phase IV, phase I/II, and phase II/III
Key regions The US, Europe, and Asia-Pacific
Key targets Gamma-Aminobutyric Acid Type A Receptor Subunit, G Protein Coupled Receptor 55 (GPR55), Voltage Gated Sodium Channel (SCN, and 5-Hydroxytryptamine Receptor 2C (5 HT2C)
Key sponsors Abbott Laboratories, GW Pharmaceuticals, Takeda Pharmaceutical, Eisai, UCB, Zogenix, Rinpharm

 Scope

  • GlobalData’s Childhood Epilepsy: Competitive Landscape in 2021 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global childhood epilepsy market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global childhood epilepsy market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Table of Contents (PowerPoint Deck)

1 Preface

1.1 Table of Contents

1.2 Abbreviations

1.3 Related Reports

1.4 Upcoming Related Reports

2 Executive Summary

2.1 Key Findings

2.2 Key Events

3 Introduction

3.1 Report Scope

3.2 Disease Overview Epidemiology Overview

3.3 Epidemiology

4 Marketed Drugs Assessment

4.1 Marketed Drugs Overview

4.2 Marketed Drug Profiles

5 Pipeline Assessment

5.1 Pipeline Overview

5.2 Pipeline Breakdown by Region

5.3 Pipeline Breakdown by Molecule Type and Target

5.4 Drug Review Designations

5.5 Phase Transition Success Rates

5.6 Likelihood of Approval

6 Clinical Trial Assessment

6.1 Clinical Trials Overview by Phase

6.2 Overview by Region

6.4 Therapy Area Perspective

6.4 Leading Sponsors

6.5 Enrollment Analytics

6.6 Feasibility Analysis

7 Commercial Assessment

7.1 Upcoming Market Catalysts

8 Social Media and Digital Marketing

8.1 Key Twitter Chatter

8.2 Top Branded Websites

8.3 Trust Flow and Citation Flow

9 Appendix

9.1 Methodology

9.2 About the Authors

9.3 About GlobalData

9.4 Contact Us

9.5 Disclaimer

Frequently asked questions

Childhood Epilepsy Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape thematic reports
Currency USD
$3,495

Can be used by individual purchaser only

$10,485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Childhood Epilepsy Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Childhood Epilepsy Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape in real time.

  • Access a live Childhood Epilepsy Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.